

## Special Issue

# Host Immunity and Vaccines for Respiratory Pathogens

### Message from the Guest Editors

We invite researchers to contribute to an upcoming Special Issue of *Vaccines* focusing on “Host Immunity and Vaccines for Respiratory Pathogens”. Respiratory infections, including influenza, RSV, SARS-CoV-2, and emerging pathogens, remain a global health challenge. This Special Issue aims to explore advances in understanding host–pathogen interactions, immune evasion mechanisms, and innovations in vaccine design, evaluation, and deployment. We welcome original research articles, reviews, and clinical studies addressing topics such as the following:

- Innate/adaptive immune responses to respiratory pathogens;
- Novel vaccine platforms (mRNA, viral vectors, etc.) and adjuvants;
- Correlates of protection and vaccine efficacy in diverse populations;
- Mucosal immunity and respiratory tract-targeted strategies;
- Challenges in vaccine equity and pandemic preparedness;
- Real world effectiveness of human vaccines.

We encourage early submissions to ensure timely consideration. Join us in advancing knowledge to combat respiratory pathogens and safeguard global health.

---

### Guest Editors

Dr. Hanqing He

Zhejiang Provincial Center for Disease Control and Prevention,  
Hangzhou, China

Dr. Yuxia Liang

Zhejiang Provincial Center for Disease Control and Prevention,  
Hangzhou, China

---

### Deadline for manuscript submissions

30 November 2026



## Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/si/241586](https://mdpi.com/si/241586)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

---

### Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College  
Roosevelt, 4331 CB Middelburg, The Netherlands

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Pharmacology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).